Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November. Two abstracts featuring SUPLEXA have been accepted for pos...
Category: Diary Marker
-
October 13, 2024
Alloplex’s Groundbreaking Cancer Immunotherapy Selected for SITC24 ‘Top 100’ Presentation
-
September 30, 2024
Dr. Borriello to present at live webinar on Immuno-Oncology R&D Challenges
Dr. Borriello will be a featured speaker at an upcoming live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, being moderated by Lumanity,...
-
July 25, 2023
Dr. Borriello to present at CHI immuno-oncology summit 2023 in Boston
Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9. The session starts at 8.55 am and Dr. Borriello’s p...
-
June 14, 2023
Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe
Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023. His presentation,...
-
May 22, 2023
Dr. Borriello attending Immuno-Oncology Xchange East Coast 2023
Alloplex CEO to participate in round table discussions
Alloplex is pleased to announce its participation in the US East Coast Immuno-Oncology Xchange to be held in Boston on May 23, 2023. Our CEO, Frank Borriello, will be in attendance and participate in a number of round table discussions. Specifically, SUPLEXA therapeutic cells will be discussed in th...
-
April 19, 2023
Alloplex to present emerging data from SUPLEXA-101 trial at World Oncology Cell Therapy Congress 2023 in Boston
The presentation will also highlight the development of an unprecedented blood-based pharmacodynamic signature of SUPLEXA activity
We are pleased to announce that Dr. Frank Borriello, Founder and CEO of Alloplex Biotherapeutics, will be presenting at the upcoming World Oncology Cell Therapy Congress, being held in Boston, MA, on April 25 & 26, 2023. The presentation will include emerging data from t...
-
July 27, 2022
Dr. Frank Borriello to speak at Gamma Delta T Therapies Summit.
July 28, 2022 in Boston.
Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11am in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous...
-
February 20, 2022
Alloplex to present Poster at AACR 2022
Alloplex’s Abstract (3599) ‘Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells’ has been accepted by AACR and is scheduled for presentation in a Poster session at the 2022 Annual Meeting. We look forward to attending this yea...
-
June 28, 2021
Alloplex to participate at Roth Capital Partners Healthcare Private Company Forum
Dr. Frank Borriello will be participating in Roth’s Capital Partners’ Virtual Healthcare Private Company Forum on June 28 as part of Cancer Panel 2: entitled Natural Killer Cell Approaches to Eradicate Tumors where he will be highlighting the differentiation of the Alloplex approach in the oncol...
-
March 22, 2021
Alloplex Biotherapeutics will attend the Innate Killer Cell Conference
The Innate Killer Cell Conference on March 24-25, 2021 held by Hanson Wade.
-
August 3, 2020
Alloplex Biotherapeutics to Present at the LifeSci Partners Summer Symposium
Alloplex CEO Frank Borriello MD, PhD will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020.
-
May 4, 2020
Alloplex Biotherapeutics Announces Participation in the Cancer Progress Meeting
Alloplex Biotherapeutics announces its participation in the Cancer Progress Meeting to be held virtually on May 5-6, 2020.